Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse (Q80777921)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 August 2007

Language	Label	Description	Also known as
English	Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse	scientific article published on 09 August 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Shimoni A

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Hardan I

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Shem-Tov N

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Rand A

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Herscovici C

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Yerushalmi R

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Nagler A

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

9 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

2109-2116

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17690701%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Bone-marrow transplantation (first of two parts).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404886

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80777921&oldid=2223753708"